Critical role of NF-&#x03BA;B in pancreatic cancer

Lakshmi Prabhu; Rasika Mundade; Murray Korc; Patrick J. Loehrer; Tao Lu

doi:10.18632/oncotarget.2624

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Critical role of NF-κB in pancreatic cancer

Lakshmi Prabhu _, Rasika Mundade, Murray Korc, Patrick J. Loehrer and Tao Lu

PDF | HTML | How to cite

Oncotarget. 2014; 5:10969-10975. https://doi.org/10.18632/oncotarget.2624

Metrics: PDF 3397 views | HTML 3633 views | ?

Abstract

Lakshmi Prabhu1, Rasika Mundade1, Murray Korc2,3, Patrick J. Loehrer4, Tao Lu1,3,5

1Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA

2Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

3Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

4Division of Hematology and Oncology, Indiana Cancer Pavilion, Indianapolis, IN, USA

5Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA

Correspondence to:

Tao Lu, e-mail: [email protected]

Keywords: NF-κB, pancreatic cancer

Received: August 26, 2014 Accepted: October 23, 2014 Published: December 19, 2014

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, and in spite of intense efforts there are limited therapeutic options for patients with PDAC. PDACs harbor a high frequency of Kras mutations and other driver mutations that lead to altered signaling pathways and contribute to therapeutic resistance. Importantly, constitutive activation of nuclear factor κB (NF-κB) is frequently observed in PDAC. An increasing body of evidence suggests that both classical and non-classical NF-κB pathways play a crucial role in PDAC development and progression. In this review, we update the most recent advances regarding different aspects of NF-κB involvement in PDAC development and progression, emphasizing its potential as a therapeutic target and the need to discover pathway-specific cytosolic NF-κB regulators which could be used to design novel therapeutic strategies for PDAC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2624

Publication Alerts

Reviews:

Critical role of NF-κB in pancreatic cancer

Abstract